1. Home
  2. OSS vs MGNX Comparison

OSS vs MGNX Comparison

Compare OSS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OSS

One Stop Systems Inc.

HOLD

Current Price

$15.42

Market Cap

229.6M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$3.53

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSS
MGNX
Founded
1998
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
229.6M
220.6M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
OSS
MGNX
Price
$15.42
$3.53
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$10.00
$5.00
AVG Volume (30 Days)
2.1M
585.6K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
133.85
N/A
EPS
N/A
N/A
Revenue
$37,027,382.00
$149,500,000.00
Revenue This Year
$22.19
N/A
Revenue Next Year
$20.67
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
34.46
N/A
52 Week Low
$2.37
$1.19
52 Week High
$16.95
$3.88

Technical Indicators

Market Signals
Indicator
OSS
MGNX
Relative Strength Index (RSI) 75.79 61.89
Support Level $7.45 $1.48
Resistance Level N/A $3.88
Average True Range (ATR) 1.46 0.22
MACD 0.67 -0.01
Stochastic Oscillator 82.15 66.68

Price Performance

Historical Comparison
OSS
MGNX

About OSS One Stop Systems Inc.

One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: